The AVID-CC trial will test the anti-tumor necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enroll up to 750 patients from community care settings throughout the UK.
Oxford to study popular prescription drug as potential COVID-19 treatment
By REUTERS
12/27/2024 01:10 AM
By AMICHAI STEIN
, WALLA!
12/26/2024 08:56 PM
By REUTERS
12/26/2024 08:38 PM
By REUTERS
12/26/2024 04:34 PM
By REUTERS
12/26/2024 03:25 PM
By REUTERS
12/26/2024 03:15 PM
By REUTERS
12/26/2024 12:41 PM